‘Dying’ for Attention: Protesters Unleash the Undeniable Power of Passively Lying on the...
No Need to Hire a Comedian When AP ‘Journalist’ Unintentionally Provides Biggest Laugh...
Andrew McCabe Says Case Against Judge Hannah Dugan is Solid but Arrest Was...
Rachel Maddow and Jamie Raskin Reveal the Dem Party’s New DEI - Dramatic...
Scott Jennings Schools CNN Panelists on why President AOC Would Be a Nightmare...
Another Night Surrounded by Democrats, Scott Jennings Attends the White House Corresponden...
Ontario Must Pay for Man to Have a Vagina Constructed While Leaving His...
Social Worker Has Absolute Meltdown Over Student Loans
Democrats Keep Proving Me Right (and I Hate It)
County Attorney Requiring Prosecutors to Consider Race When Offering Plea Deals
Hello, Gaslight! Democrat Jason Crow Earns EPIC Ratio for Lying About What His...
Susan Rice Goes on a Rant About White Male Christian Cisgender Macho MAGA...
J.K. Rowling Wants THIS Video Saved for Future Generations to See How Stupid...
Conor McGregor Expresses His Support for Irish Marchers Against Mass Immigration
Cause They ARE! Adam Schiff Tells Bill Maher Even Voters In San Francisco...

Pfizer delays its EUA request for a 2-dose Covid vaccine for kids under 5, will wait for data on a 3-dose vaccine instead

Pfizer told the FDA on Friday that it wants a delay on the company’s EUA request for a two-dose Covid vaccine for children under five. . .

Advertisement

. . .and that’s because Pfizer thinks three doses “may provide a higher level of protection in this age group”:

Here’s the statement from the FDA:

The U.S. Food and Drug Administration has been notified by Pfizer that new data have recently emerged regarding its emergency use authorization request for the use of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age. As part of its rolling submission, the company recently notified the agency of additional findings from its ongoing clinical trial. Based on the agency’s preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization.

Advertisement

Something just doesn’t add up here, right?

The FDA was going to meet on February 15 to discuss the authorization for this age group:

Pfizer expects to have data from the three-dose vaccine in April:

Advertisement

In other words, “back to the drawing board”:

Do you mean to tell us our health experts have a messaging problem?

***

Join the conversation as a VIP Member

Recommended

Trending on Twitchy Videos